Vendor review
Shanghai Leader Peptide Biotechnology reviews
Shanghai Leader Peptide Biotechnology reviews from 83 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Shanghai Leader Peptide Biotechnology legit? See what its vials showed.
What the lab tests show
83 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 6, 2026 | Tirzepatide | 99.9 % | 31.6 mg of 30 mg (5 %) | Pass | View |
| Sep 25, 2026 | Tirzepatide | 29.3 % | 5.86 mg of 20 mg (-71 %) | Pass | View |
| Sep 21, 2026 | Tesamorelin | 96.04 % | 10.57 mg of 20 mg (-47 %) | Pass | View |
| Sep 20, 2026 | Tirzepatide | 99.99 % | 31.6 mg of 30 mg (5 %) | Pass | View |
| Sep 20, 2026 | Retatrutide | 99.79 % | 33.71 mg of 30 mg (12 %) | Pass | View |
| Sep 16, 2026 | Tirzepatide | 99.9 % | 33.1 mg of 30 mg (10 %) | Pass | View |
| Sep 16, 2026 | Retatrutide | 99.9 % | 34.4 mg of 30 mg (15 %) | Pass | View |
| Sep 15, 2026 | GHK-Cu | 99.9 % | 68.6 mg of 100 mg (-31 %) | Pass | View |
| Sep 9, 2026 | Retatrutide | 92.5 % | 12.3 mg of 20 mg (-39 %) | Pass | View |
| Aug 25, 2026 | Tirzepatide | 60 mg | Fail | View | |
| Jul 30, 2026 | Retatrutide | 99.6 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Jul 22, 2026 | Tirzepatide | 99.9 % | 55.6 mg of 60 mg (-7 %) | Pass | View |
| Jul 20, 2026 | Retatrutide | 99.8 % | 11 mg of 10 mg (10 %) | Pass | View |
| Jul 20, 2026 | Retatrutide | 96.4 % | 18.7 mg of 20 mg (-7 %) | Pass | View |
| Jul 20, 2026 | Tirzepatide | 99.9 % | 17.6 mg of 20 mg (-12 %) | Pass | View |
| Jul 17, 2026 | Ipamorelin | 99.7 % | 5.56 mg of 5 mg (11 %) | Pass | View |
| Jul 13, 2026 | Tirzepatide | 99.9 % | 17.3 mg of 20 mg (-14 %) | Pass | View |
| Jul 13, 2026 | GHK-Cu | 99.9 % | 116.8 mg of 100 mg (17 %) | Pass | View |
| Jun 5, 2026 | GHK-Cu | 50 mg | View | ||
| Jun 4, 2026 | Tesamorelin | 99.7 % | 12.6 mg of 10 mg (26 %) | Pass | View |
| Jun 2, 2026 | BPC-157 | 99.9 % | 9.65 mg of 10 mg (-3 %) | Pass | View |
| Jun 1, 2026 | GHK-Cu | 99.6 % | 56.2 mg of 50 mg (12 %) | Pass | View |
| May 25, 2026 | Tirzepatide | 99.9 % | 48.2 mg of 40 mg (21 %) | Pass | View |
| May 13, 2026 | Retatrutide | 99.6 % | 10.1 mg of 10 mg (1 %) | Pass | View |
| May 13, 2026 | GHK-Cu | 99.6 % | 104 mg of 100 mg (4 %) | Pass | View |
| May 11, 2026 | NAD+ | 1000 mg | View | ||
| May 8, 2026 | Tirzepatide | 99.9 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| May 8, 2026 | NAD+ | 99.9 % | 1321.3 mg of 1000 mg (32 %) | Pass | View |
| May 6, 2026 | Retatrutide | 20 mg | Fail | View | |
| May 6, 2026 | Retatrutide | 5 mg | Fail | View | |
| May 6, 2026 | Tesamorelin | 99.9 % | 8.63 mg of 10 mg (-14 %) | Pass | View |
| May 6, 2026 | Ipamorelin | 99.9 % | 11 mg of 10 mg (10 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 19.9 mg of 20 mg (-1 %) | Pass | View |
| Apr 23, 2026 | Tesamorelin | 98.9 % | 8.8 mg of 10 mg (-12 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 98.7 % | 5.3 mg of 5 mg (6 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 99.9 % | 32 mg of 30 mg (7 %) | Pass | View |
| Apr 21, 2026 | Retatrutide | 99.7 % | 20.4 mg of 20 mg (2 %) | Pass | View |
| Apr 13, 2026 | Retatrutide | 99.4 % | 8.7 mg of 10 mg (-13 %) | Pass | View |
| Apr 13, 2026 | Retatrutide | 99.5 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Apr 13, 2026 | Retatrutide | 10 mg | View | ||
| Apr 13, 2026 | Retatrutide | 10 mg | View | ||
| Apr 13, 2026 | Tesamorelin | 99.8 % | 11.9 mg of 10 mg (19 %) | Pass | View |
| Apr 13, 2026 | Tirzepatide | 99.7 % | 33.5 mg of 30 mg (12 %) | Pass | View |
| Apr 13, 2026 | Tirzepatide | 30 mg | View | ||
| Apr 3, 2026 | Cagrilintide | 99.6 % | 11.8 mg of 10 mg (18 %) | Pass | View |
| Apr 2, 2026 | Tirzepatide | 99.7 % | 20.3 mg of 20 mg (2 %) | Pass | View |
| Apr 2, 2026 | GHK-Cu | 99.4 % | 86.9 mg of 100 mg (-13 %) | Pass | View |
| Mar 29, 2026 | Tesamorelin | 99.8 % | 14.3 mg of 10 mg (43 %) | Pass | View |
| Mar 19, 2026 | Retatrutide | 99.9 % | 15.9 mg of 15 mg (6 %) | Pass | View |
| Mar 16, 2026 | Retatrutide | 99.7 % | 20.9 mg of 20 mg (4 %) | Pass | View |
| Mar 16, 2026 | Tesamorelin | 99.8 % | 27.4 mg of 20 mg (37 %) | Pass | View |
| Mar 13, 2026 | GHK-Cu | 99.7 % | 43.9 mg of 50 mg (-12 %) | Pass | View |
| Mar 13, 2026 | Retatrutide | 99.4 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Mar 10, 2026 | Tirzepatide | 99.9 % | 19.4 mg of 20 mg (-3 %) | Pass | View |
| Mar 10, 2026 | Retatrutide | 99.4 % | 29.3 mg of 30 mg (-2 %) | Pass | View |
| Mar 10, 2026 | NAD+ | 99.9 % | 464 mg of 500 mg (-7 %) | Pass | View |
| Mar 4, 2026 | Tirzepatide | 20 mg | Fail | View | |
| Mar 4, 2026 | BPC-157 | 99.9 % | 11.3 mg of 10 mg (13 %) | Pass | View |
| Mar 2, 2026 | Tirzepatide | 99.9 % | 8.62 mg of 10 mg (-14 %) | Pass | View |
| Mar 2, 2026 | GHK-Cu | 99.87 % | 62.5 mg of 50 mg (25 %) | Pass | View |
What Shanghai Leader Peptide Biotechnology sells
No current listings on record.
About Shanghai Leader Peptide Biotechnology
Finnrick has tested 83 samples from Shanghai Leader Peptide Biotechnology across 8 products.